NCT01738347View on ClinicalTrials.gov

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Relapsing-remitting Multiple Sclerosis (rrMS)
Interventions
DRUG

Arm 1 - GEH120714 (18F) Injection

Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).

Trial Locations (1)

Unknown

St. Joseph Healthcare, Hamilton

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
collaborator

Centre for Probe Development and Commercialization

OTHER

lead

GE Healthcare

INDUSTRY